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Purpose of the study
Previous studies of our team have shown that Romanian
teenagers horizontally infected with HIV in early child-
hood, have a high prevalence of HBV co-infection (78.3%
being anti-HBc positive vs. 21.8% of age-matched HIV-
negative controls). Our aim was to investigate the fre-
quency of mutations and variables potentially associated
with an increased risk of liver disease evolution in HIV/
HBV co-infected individuals receiving 2NRTI + 1PI
boosted with ritonavir.
Methods
We investigated 38 HIV+ adolescents (mean age 13.8 ±
1.3 years) with constant detectable HBV viral load, of
whom 92.3% were chronic HBsAg carriers, 61.53% were
HBeAg+, and 68.2% had lamivudine (LAM) in their regi-
men. HBV genotype was determined using commercial
Line Probe Assay (Innogenetics) and sequencing of the
HIV pol gene was carried out using Trugene genotyping
kits (Bayer Diagnostics Inc.); for HIV subtyping the nucle-
otide sequences were submitted to the Stanford database.
Summary of results
All patients were infected with the HIV F1 subtype, while
HBV genotype A was the most prevalent (84.6% of cases).
A small percentage of patients presented other HBV geno-
types (7.7% D and 7.7% both A and D). In spite of the
long evolution of HIV infection only 23.07% of patients
had worsened HIV-related parameters (CD4 count less
than 100 cell/μL, average HIV titer above 750,000 copies
RNA HIV/ml), associated with increased transaminases
levels (average values 72 mg/dl). No correlation between
HIV viral loads or the degree of immunosupression and
HBV viral load was found. 75% of the patients with LAM
exposure vs. 55.5% patients without LAM were HBeAg+.
HIV pol gene sequencing demonstrated that only 10
patients had a high degree of resistance to LAM, including
those who had never received this drug. The most com-
mon mutation in the RT gene was M184V/I (that causes
high-level resistance to LAM, but also confers a dimin-
ished HIV replicative fitness); associated with type 2
TAMs: D67N, K70R, T215F, and K219Q/E that confer
NRTI resistance.
Conclusion
We suggest that association of HIV F subtype and geno-
type A of HBV may generate a less severe evolution of HBV
infection irrespective of the LAM treatment with less fre-
quent mutations in pol HIV gene. The absence of type 1
TAMs opens the possibility to treat these patients with ten-
ofovir-containing regimens with a good virological
response. Further studies are needed to clarify the kinetics
and significance of different mutation patterns observed
in naïve vs. LAM treated HIV/HBV co-infected patients.
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